KINETIC-TECHNOLOGIES
15.11.2022 07:01:51 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced today the KTA1140 IEEE 802.3bt-compliant Powered Device Interface IC and the KTB1095 synchronous flyback control IC with integrated digital isolated feedback as the latest additions to their PoE and DC-DC Converter product lines.
Fully compliant with IEEE 802.3bt, 802.3at and 802.3af standards, the KTA1140 integrates input surge protection, a PD controller with 100V, low resistance 0.1Ω hot-swap MOSFET, which fully supports input power levels up to 90W. The PD controller also includes eight-event classification, ATDET, PD Detect, over temperature protection and under voltage lockout (UVLO). The KTA1140 is also designed to provide seamless support for local supplies down to 9.5V.
The KTB1095 is a highly integrated synchronous flyback converter with internal feedback utilizing a 3000VRMS digital isolator, designed to eliminate the need for an external opto-coupler, reducing cost and size. Operating over a wide operating voltage range from 5V to 100V, the KTB1095 includes both primary and secondary side, high current MOSFET drivers and employs current-mode constant on-time control for fast transient response. Featuring an adjustable soft-start function to limit start-up in-rush current, the KTB1095 also includes input voltage UVLO, output over-voltage-protection (OVP), cycle-by-cycle current limit, short-circuit protection and thermal shutdown.
“Our goal at Kinetic is to make it as easy as possible for our customers to design their power supplies,” said Erik Ogren, Kinetic Technologies’ Senior Director of Marketing. “The KTA1140 supports Class 8, 90W designs with its ultra-low resistance hot-swap MOSFET and simplifies system designs with local voltage support. KTB1095 takes advantage of Kinetic’s Tru-Iso™ technology to deliver integrated 3000V-rms on-chip digital isolator feedback, reducing BOM count and PCB area.”
KTA1140 and KTB1095 are sampling now, with production expected to begin in the first quarter of 2023.
Visit Kinetic Technologies for further information.
Key Product Highlights:
KTA1140 – PoE 802.3bt PD Interface
-
Fully supports IEEE® 802.3bt
- Input Power Levels Up to 90W
- Class 0-8 for PoE PD
- Compatible with IEEE® 802.3af/at
- IEC 61000-4-2/3/4/5/6 requirements for EMC
- Seamless support for local power down to 9.5V
- Programmable DC current limit
- Low resistance (typ. 0.1Ω) Hot Swap MOSFET
- 5x5 mm, 20 lead QFN Package
KTB1095 – 100V Synchronous Flyback Controller with Digital Isolation
- Wide 5V to 100V Operating Voltage Range
-
Integrated Digital Isolator Feedback
- 3000V-rms Integrated Isolation
- ±1% Voltage Reference
-
Integrated primary and secondary side MOSFET Drivers
- 3A Sink / 2A Source driving capability
- Adjustable Switching Frequency from 100kHz to 700kHz
- Integrated Protection: Cycle-by-cycle current limit, Input UVLO, OCP, SCP, TSP
- SOIC-16 Wide Body (10.3mm x 7.5mm) Package
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
